Individual generic drug information

estradiol hemihydrate

Reference monograph

Part of registered formulation

ESTRADIOL HEMIHYDRATE

Reference record: Estradiol
Source: BNF 80 (2020–2021)
Printed source pages: 821, 822, 823, 824
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Estradiol only.

Indications And Dose

BEDOL ® Menopausal symptoms | Osteoporosis prophylaxis ▶BY MOUTH ▶Adult: 2 mg daily, started on day 1–5 of menstruation (or at any time if cycles have ceased or are infrequent), to be taken with cyclical progestogen for 12–14 days of each cycle in women with a uterus ELLESTE SOLO ® MX Menopausal symptoms ▶BY TRANSDERMAL APPLICATION ▶Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with MX 40, subsequently adjust according to response Osteoporosis prophylaxis ▶BY TRANSDERMAL APPLICATION ▶Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with MX 80, subsequently adjust according to response ELLESTE-SOLO ® 1-MG Menopausal symptoms ▶BY MOUTH ▶Adult: 1 mg daily, starting on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), to be taken with cyclical progestogen for 12–14 days of each cycle in women with a uterus ELLESTE-SOLO ® 2-MG Menopausal symptoms not controlled with lower strength | Osteoporosis prophylaxis ▶BY MOUTH ▶Adult: 2 mg daily, started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), to be given with cyclical progestogen for 12–14 days of each cycle in women with a uterus ESTRADERM MX ® Menopausal symptoms ▶BY TRANSDERMAL APPLICATION ▶Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus, initiate therapy with MX25 for ﬁrst 3 months; subsequently adjust according to response Osteoporosis prophylaxis ▶BY TRANSDERMAL APPLICATION ▶Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus, initiate therapy with MX50; subsequently adjust according to response ESTRADOT ® Menopausal symptoms ▶BY TRANSDERMAL APPLICATION ▶Adult: Apply 1 patch twice weekly continuously, to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with 25 patch for 3 months; subsequently adjust according Endocrine system to response Osteoporosis prophylaxis ▶BY TRANSDERMAL APPLICATION ▶Adult: Apply 1 patch twice weekly continuously, to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with 50 patch; subsequently adjust according to response EVOREL ® Menopausal symptoms | Osteoporosis prophylaxis ▶BY TRANSDERMAL APPLICATION ▶Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, therapy should be initiated with Evorel 50 patch; subsequently adjust according to response; dose may be reduced to Evorel 25 patch after ﬁrst month if necessary for menopausal symptoms only FEMSEVEN ® Menopausal symptoms | Osteoporosis prophylaxis ▶BY TRANSDERMAL APPLICATION ▶Adult: Apply 1 patch once weekly continuously, to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with FemSeven 50 patches for the ﬁrst few months, subsequently adjust according to response OESTROGEL ® Menopausal symptoms ▶TO THE SKIN ▶Adult: Apply 1.5 mg once daily continuously, increased if necessary up to 3 mg after 1 month continuously, to be applied over an area twice that of the template provided, starting within 5 days of menstruation (or anytime if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus Osteoporosis prophylaxis ▶TO THE SKIN ▶Adult: Apply 1.5 mg once daily continuously, to be applied over an area twice that of the template provided, starting within 5 days of menstruation (or anytime if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus DOSE EQUIVALENCE AND CONVERSION ▶With topical use ▶For Oestrogel ®: 2 measures is equivalent to estradiol 1.5 mg. PROGYNOVA ® Menopausal symptoms ▶BY MOUTH ▶Adult: 1–2 mg daily continuously, to be started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), to be taken with cyclical progestogen for 12–14 days of each cycle in women continued → with a uterus Osteoporosis prophylaxis ▶BY MOUTH ▶Adult: 2 mg daily continuously, to be taken with cyclical progestogen for 12–14 days of each cycle in women with a uterus PROGYNOVA ® TS Menopausal symptoms | Osteoporosis prophylaxis ▶BY TRANSDERMAL APPLICATION ▶Adult: Apply 1 patch once weekly continuously, Endocrine system alternatively apply 1 patch once weekly for 3 weeks, followed by a 7-day patch-free interval (cyclical), to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with Progynova TS 50, subsequently adjust according to response, women receiving Progynova TS 100 patches for menopausal symptoms may continue with this strength for osteoporosis prophylaxis SANDRENA ® Menopausal symptoms ▶TO THE SKIN ▶Adult: Apply 1 mg once daily, to be applied over area 1–2 times size of hand; with cyclical progestogen for 12–14 days of each cycle in women with a uterus, dose may be adjusted after 2–3 cycles to lowest effective dose; usual dose 0.5–1.5 mg daily ZUMENON ® Menopausal symptoms ▶BY MOUTH ▶Adult: Initially 1 mg daily, to be started within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), increased if necessary to 2 mg daily, to be taken with a cyclical progestogen for 12–14 days of each cycle in women with a uterus Osteoporosis prophylaxis ▶BY MOUTH ▶Adult: 2 mg daily, to be taken with a cyclical progestogen for 12–14 days of each cycle in women with a uterus

Source pages 821, 822

Contra Indications

Active arterial thromboembolic disease (e.g. angina or myocardial infarction). history of breast cancer. history of venous thromboembolism. oestrogen-dependent cancer. recent arterial thromboembolic disease (e.g. angina or myocardial infarction). thrombophilic disorder. undiagnosed vaginal bleeding. untreated endometrial hyperplasia

Source page 822

Cautions

Acute porphyrias p. 1120. diabetes (increased risk of heart disease). factors predisposing to thromboembolism. history of breast nodules—closely monitor breast status (risk of breast cancer). history of endometrial hyperplasia. history of ﬁbrocystic disease— closely monitor breast status (risk of breast cancer). hypophyseal tumours. increased risk of gall-bladder disease. migraine (or migraine-like headaches). presence of antiphospholipid antibodies (increased risk of thrombotic events). prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer. risk factors for oestrogen-dependent tumours (e.g. breast cancer in ﬁrst-degree relative). symptoms of endometriosis may be exacerbated. uterine ﬁbroids may increase in size CAUTIONS, FURTHER INFORMATION ▶Risk of endometrial cancer The increased risk of endometrial cancer depends on the dose and duration of oestrogen- only HRT. In women with a uterus using systemic preparations, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer. ▶Risk of ovarian cancer Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer. This excess risk disappears within a few years of stopping. ▶Risk of venous thromboembolism Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the ﬁrst year of use. In women who have predisposing factors (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the beneﬁts. Travel involving prolonged immobility further increases the risk of deep vein thrombosis. ▶Risk of stroke Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT increases the risk of stroke. ▶Risk of coronary heart disease HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women. ▶Risk of breast cancer with systemic use HRT use is associated with an increased risk of breast cancer—see Important safety information. Radiological detection of breast cancer can be made more difﬁcult as mammographic density can increase with HRT use.

Source page 822

Safety

Extracted information for Estradiol only.

Important Safety Information

MHRA/CHM ADVICE: HORMONE REPLACEMENT THERAPY (HRT): FURTHER INFORMATION ON THE KNOWN INCREASED RISK OF BREAST CANCER WITH HRT AND ITS PERSISTENCE AFTER STOPPING (SEPTEMBER 2019) ▶With oral use or topical use or transdermal use Data from a meta-analysis of more than 100 000 women with breast cancer have conﬁrmed that the risk of breast cancer is increased with the use of all forms of systemic HRT, except vaginal oestrogens, for longer than 1 year. Findings have shown that the risk increases further with longer duration of use, is higher for combined oestrogen-progestogen HRT than with oestrogen-only HRT, and persists for more than 10 years after stopping HRT. Healthcare professionals are advised to only prescribe HRT for the relief of postmenopausal symptoms that adversely affect quality of life, and to regularly review patients to ensure that it is used for the shortest time and at the lowest dose. Patients currently and previously on HRT should be informed of the risk and to be vigilant for signs of breast cancer; they should also be encouraged to attend breast screening appointments.

Source page 822

Interactions

→Appendix 1: hormone replacement therapy

Source page 822

Side Effects

GENERAL SIDE-EFFECTS ▶Common or very common Headaches. nausea. skin reactions ▶Uncommon Hypertension SPECIFIC SIDE-EFFECTS ▶Common or very common ▶With oral use Asthenia. gastrointestinal discomfort. gastrointestinal disorders. haemorrhage. menstrual cycle irregularities. muscle complaints. pelvic pain. weight changes ▶With transdermal use Abdominal pain. breast abnormalities . menstrual cycle irregularities. uterine disorders. vaginal discharge. weight changes ▶Uncommon ▶With oral use Anxiety. back pain. breast abnormalities. cervical abnormalities. cystitis-like symptom. depression. dizziness. embolism and thrombosis. erythema nodosum. gallbladder disorder. oedema. palpitations. peripheral vascular disease. tumour growth. visual impairment. vulvovaginal candidiasis ▶With transdermal use Asthenia. breast neoplasm benign. depression. ﬂatulence. increased risk of infection. leiomyoma. mood swings. venous thromboembolism. vertigo. vomiting ▶Rare or very rare ▶With oral use Angioedema. cerebrovascular insufﬁciency. chorea. contact lens intolerance. haemolytic anaemia. hepatic disorders. hirsutism. malaise. myocardial infarction. sexual dysfunction. steepening of corneal curvature. vaginal discharge. vomiting ▶With transdermal use Epilepsy exacerbated. galactorrhoea. glucose tolerance impaired. libido disorder ▶Frequency not known ▶With oral use Carbohydrate metabolism change. epilepsy exacerbated. hypertriglyceridaemia. increased risk of coronary artery disease. neoplasms. pancreatitis. systemic lupus erythematosus (SLE) SIDE-EFFECTS, FURTHER INFORMATION Cyclical HRT (where a progestogen is taken for 12–14 days of each 28-day oestrogen treatment cycle) usually results in regular withdrawal bleeding towards the end of the progestogen. Continuous combined HRT commonly produces irregular breakthrough bleeding in the ﬁrst 4–6 months of treatment. Bleeding beyond 6 months or after a spell of amenorrhoea requires further investigation to exclude serious gynaecological pathology.

Source pages 822, 823

Conception And Contraception

HRT does not provide contraception and a woman is considered potentially fertile for 2 years after her last menstrual period if she is under 50 years, and for 1 year if she is over 50 years. A woman who is under 50 years and free of all risk factors for venous and arterial disease can use a low-oestrogen combined oral contraceptive pill to provide both relief of menopausal symptoms and contraception; it is recommended that the oral contraceptive be stopped at 50 years of age since there are more suitable alternatives. If any potentially fertile woman needs HRT, non-hormonal contraceptive measures (such as condoms) are necessary. Measurement of follicle-stimulating hormone can help to determine fertility, but high measurements alone (particularly in women aged under 50 years) do not necessarily preclude the possibility of becoming pregnant.

Source page 823

Pregnancy

Not known to be harmful.

Source page 823

Breast Feeding

Avoid; adverse effects on lactation.

Source page 823

Hepatic Impairment

Manufacturer advises caution; avoid in acute or active disease.

Source page 823

Monitoring Requirements

▶History of breast nodules or ﬁbrocystic disease—closely monitor breast status (risk of breast cancer). ▶The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.

Source page 823

Dose and formulations

Extracted information for Estradiol only.

Directions For Administration

▶With transdermal use Patch should be removed after 3–4 days (or once a week in case of 7-day patch) and replaced with fresh patch on slightly different site; recommended sites: clean, dry, unbroken areas of skin on trunk below waistline; not to be applied on or near breasts or under waistband. If patch falls off in bath allow skin to cool before applying new patch.

Source page 823

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Bedol (ReSource Medical UK Ltd) Estradiol 2 mg Bedol 2mg tablets | 84 tablet P £5.07 DT = £5.06 ▶Elleste Solo (Mylan) Estradiol 1 mg Elleste Solo 1mg tablets | 84 tablet P £5.06 DT = £5.06 Estradiol 2 mg Elleste Solo 2mg tablets | 84 tablet P £5.06 DT = £5.06 ▶Progynova (Bayer Plc) Estradiol valerate 1 mg Progynova 1mg tablets | 84 tablet P £7.30 DT = £7.30 Estradiol valerate 2 mg Progynova 2mg tablets | 84 tablet P £7.30 DT = £7.30 ▶Zumenon (Mylan) Estradiol 1 mg Zumenon 1mg tablets | 84 tablet P £6.89 DT = £5.06 Estradiol 2 mg Zumenon 2mg tablets | 84 tablet P £6.89 DT = £5.06 Transdermal patch ▶Elleste Solo MX (Mylan) Estradiol 40 microgram per 24 hour Elleste Solo MX 40 transdermal patches | 8 patch P £5.19 DT = £5.19 Estradiol 80 microgram per 24 hour Elleste Solo MX 80 transdermal patches | 8 patch P £5.99 DT = £5.99 ▶Estraderm MX (Norgine Pharmaceuticals Ltd) Estradiol 25 microgram per 24 hour Estraderm MX 25 patches | 8 patch P £5.50 DT = £3.42 | 24 patch P £16.46 DT = £16.46 Estradiol 50 microgram per 24 hour Estraderm MX 50 patches | 8 patch P £5.51 DT = £3.88 | 24 patch P £16.46 DT = £11.66 Estradiol 75 microgram per 24 hour Estraderm MX 75 patches | 8 patch P £6.42 DT = £4.12 | 24 patch P £19.27 Estradiol 100 microgram per 24 hour Estraderm MX 100 patches | 8 patch P £6.66 DT = £4.28 | 24 patch P £19.99 DT = £19.99 ▶Estradot (Novartis Pharmaceuticals UK Ltd) Estradiol 25 microgram per 24 hour Estradot 25micrograms/24hours patches | 8 patch P £5.99 DT = £3.42 Estradiol 37.5 microgram per 24 hour Estradot 37.5micrograms/24hours patches | 8 patch P £6.00 DT = £6.00 Estradiol 50 microgram per 24 hour Estradot 50micrograms/24hours patches | 8 patch P £6.02 DT = £3.88 Estradiol 75 microgram per 24 hour Estradot 75micrograms/24hours patches | 8 patch P £7.00 DT = £4.12 Estradiol 100 microgram per 24 hour Estradot 100micrograms/24hours patches | 8 patch P £7.27 DT = £4.28 ▶Evorel (Theramex HQ UK Ltd) Estradiol 25 microgram per 24 hour Evorel 25 patches | 8 patch P £3.42 DT = £3.42 Estradiol 50 microgram per 24 hour Evorel 50 patches | 4 patch P s DT = £6.04 | 8 patch P £3.88 DT = £3.88 | 24 patch P £11.66 DT = £11.66 Estradiol 75 microgram per 24 hour Evorel 75 patches | 8 patch P £4.12 DT = £4.12 Estradiol 100 microgram per 24 hour Evorel 100 patches | 8 patch P £4.28 DT = £4.28 ▶FemSeven (Theramex HQ UK Ltd) Estradiol 50 microgram per 24 hour FemSeven 50 patches | 4 patch P £6.04 DT = £6.04 | 12 patch P £18.02 DT = £18.02 Estradiol 75 microgram per 24 hour FemSeven 75 patches | Endocrine system 4 patch P £6.98 Estradiol 100 microgram per 24 hour FemSeven 100 patches | 4 patch P £7.28 DT = £7.28 ▶Progynova TS (Bayer Plc) Estradiol 50 microgram per 24 hour Progynova TS 50micrograms/24hours transdermal patches | 12 patch P £18.90 DT = £18.02 Estradiol 100 microgram per 24 hour Progynova TS 100micrograms/24hours transdermal patches | 12 patch P £20.70 DT = £20.70 Gel EXCIPIENTS: May contain Propylene glycol ▶Oestrogel (Besins Healthcare (UK) Ltd) Estradiol 600 microgram per 1 gram Oestrogel Pump-Pack 0.06% gel | 80 gram P £4.80 DT = £4.80 ▶Sandrena (Orion Pharma (UK) Ltd) Estradiol (as Estradiol hemihydrate) 500 microgram Sandrena 500microgram gel sachets | 28 sachet P £5.08 DT = £5.08 Estradiol (as Estradiol hemihydrate) 1 mg Sandrena 1mg gel sachets | 28 sachet P £5.85 DT = £5.85 | 91 sachet P £17.57 Combinations available: Estradiol with dydrogesterone, p. 803 . Estradiol with levonorgestrel, p. 804. Estradiol with medroxyprogesterone, p. 804. Estradiol with norethisterone, p. 805

Source pages 823, 824

Clinical care

Extracted information for Estradiol only.

Patient And Carer Advice

▶With transdermal use Patient counselling is advised for estradiol patches (administration). ▶With topical use Patient counselling is advised for estradiol gels (administration). Information sheet ▶With oral use or topical use or transdermal use The MHRA has Endocrine system provided a patient information sheet to aid healthcare professionals when counselling women on the risk of breast cancer with HRT use. OESTROGEL ® ▶With topical use Apply gel to clean, dry, intact skin such as arms, shoulders or inner thighs and allow to dry for 5 minutes before covering with clothing. Not to be applied on or near breasts or on vulval region. Avoid skin contact with another person (particularly male) and avoid other skin products or washing the area for at least 1 hour after application. SANDRENA ® ▶With topical use Apply gel to intact areas of skin such as lower trunk or thighs, using right and left sides on alternate days. Wash hands after application. Not to be applied on the breasts or face and avoid contact with eyes. Allow area of application to dry for 5 minutes and do not wash area for at least 1 hour.

Source page 823

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

2 mg daily, started on day 1–5 of menstruation

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

1 mg daily, starting on day 1 of menstruation (or

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

2 mg daily, started on day 1 of menstruation (or

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously, to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously, to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch once weekly continuously, to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1.5 mg once daily continuously, increased

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1.5 mg once daily continuously, to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

1–2 mg daily continuously, to be started on day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

2 mg daily continuously, to be taken with

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch once weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Adults

First line only; read the complete Indications and dose section above.

Apply 1 mg once daily, to be applied over area

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Adults

First line only; read the complete Indications and dose section above.

Initially 1 mg daily, to be started within 5 days of

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Adults

First line only; read the complete Indications and dose section above.

2 mg daily, to be taken with a cyclical

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

estradiol hemihydrate

Reference monograph

Part of registered formulation

ESTRADIOL HEMIHYDRATE

Reference record: Estradiol
Source: BNF 80 (2020–2021)
Printed source pages: 821, 822, 823, 824
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Estradiol only.

Indications And Dose

Source pages 821, 822

Contra Indications

Source page 822

Cautions

Source page 822

Safety

Extracted information for Estradiol only.

Important Safety Information

Source page 822

Interactions

→Appendix 1: hormone replacement therapy

Source page 822

Side Effects

Source pages 822, 823

Conception And Contraception

Source page 823

Pregnancy

Not known to be harmful.

Source page 823

Breast Feeding

Avoid; adverse effects on lactation.

Source page 823

Hepatic Impairment

Manufacturer advises caution; avoid in acute or active disease.

Source page 823

Monitoring Requirements

Source page 823

Dose and formulations

Extracted information for Estradiol only.

Directions For Administration

Source page 823

Medicinal Forms

Source pages 823, 824

Clinical care

Extracted information for Estradiol only.

Patient And Carer Advice

Source page 823

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

2 mg daily, started on day 1–5 of menstruation

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

1 mg daily, starting on day 1 of menstruation (or

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

2 mg daily, started on day 1 of menstruation (or

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously, to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously, to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch twice weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch once weekly continuously, to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1.5 mg once daily continuously, increased

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

Apply 1.5 mg once daily continuously, to be

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

1–2 mg daily continuously, to be started on day

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 821

Adults

First line only; read the complete Indications and dose section above.

2 mg daily continuously, to be taken with

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Adults

First line only; read the complete Indications and dose section above.

Apply 1 patch once weekly continuously,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Adults

First line only; read the complete Indications and dose section above.

Apply 1 mg once daily, to be applied over area

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Adults

First line only; read the complete Indications and dose section above.

Initially 1 mg daily, to be started within 5 days of

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Adults

First line only; read the complete Indications and dose section above.

2 mg daily, to be taken with a cyclical

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 822

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.